This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require physician evaluation before use. Consult your healthcare provider before starting any ED treatment. Do not combine prescription medications without physician guidance. This article may contain affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.
By VFM Research Desk | Last verified: May 2026
Editorial note: This article covers prescription drug pharmacology. While all claims are sourced from FDA prescribing information, peer-reviewed publications, and verified clinical literature as cited, this content has not been independently reviewed by a named licensed medical professional. Readers should consult a qualified healthcare provider before making any prescription treatment decisions.
Quick Answer: Sildenafil, tadalafil, and vardenafil are the three FDA-approved PDE5 inhibitors for erectile dysfunction. All three slow the breakdown of cGMP to sustain the vascular response that enables an erection, and all three require sexual arousal to work — none produces erections independently. Sildenafil works fastest on an empty stomach (peaks 30–60 min, lasts 4–6 hr) but is significantly slowed by food. Tadalafil lasts longest (up to 36 hr, available for daily use) and is minimally affected by food. Vardenafil may offer faster onset in some patients but carries a specific QT prolongation caution. Apomorphine operates through an entirely different dopamine pathway and holds US FDA approval only for Parkinson’s disease.
Most men researching ED medication are really asking one question: which one is right for me, and why would one work better than another? The answer comes down to mechanism, dose, timing, food interactions, and whether the problem is primarily vascular, neurological, or both. This guide covers the published pharmacology, the dose math framework for evaluating any product in this category, and the precise differences between these medications that most marketing pages and many review articles never clearly explain.
How to Read Prescription Research
Two principles separate useful information about ED medication from marketing noise: mechanism specificity and dose specificity. A compound that demonstrably inhibits PDE5 degradation of cGMP is working through a defined, evidence-supported pathway. A supplement that vaguely “supports blood flow” may or may not be doing anything relevant to that mechanism. Similarly, “contains sildenafil” and “contains sildenafil at 50mg” are not the same statement — effective dose ranges come from published prescribing information and clinical trials, not from product pages or review articles.
For prescription ED medications, the authoritative sources are FDA prescribing information documents (available at FDA.gov for each approved medication), peer-reviewed pharmacokinetic studies in publications including the British Journal of Clinical Pharmacology and the Journal of Sexual Medicine, and AUA clinical practice guidelines. Those are the sources the dose math framework below draws from.
The Dose Math Framework
When evaluating any ED prescription or compounded formulation, five variables determine how a medication actually performs for a specific individual: starting dose, peak plasma concentration timing (Tmax), half-life, effective window duration, and food interaction magnitude. For compounded multi-ingredient formulations, the clinician sets the dose ratios — ask specifically what dose of each component has been prescribed and why that ratio was chosen for your health profile.
Sildenafil: Approved dose range 25mg–100mg on-demand. Tmax: 30–120 minutes (faster fasted, slower with high-fat meal). Half-life: approximately 3–5 hours. Effective window: 4–6 hours. Maximum frequency: once per 24 hours. Food interaction: significant — high-fat meals delay and reduce absorption meaningfully.
Tadalafil: Approved dose range 5mg–20mg on-demand; 2.5–5mg for daily use. Tmax: approximately 2 hours. Half-life: approximately 17.5 hours. Effective window: up to 36 hours on-demand; continuous for daily use. Maximum frequency on-demand: once per 24 hours at doses above 10mg. Food interaction: minimal — not significantly affected by food intake.
Vardenafil: Approved dose range 5mg–20mg on-demand. Tmax: approximately 30–120 minutes (faster fasted). Half-life: approximately 4–5 hours. Effective window: 4–5 hours. Food interaction: moderate — similar to sildenafil but generally less pronounced. QT prolongation caution: present — not shared by sildenafil or tadalafil at the same specificity level.
Sildenafil — Research Overview
Sildenafil is the most extensively studied prescription ED medication in existence, with a 28-year post-approval evidence base and one of the best-characterized pharmacokinetic profiles of any drug in clinical use. FDA-approved in 1998, it works by inhibiting PDE5, the enzyme responsible for breaking down cGMP in smooth muscle tissue in the corpus cavernosum. By slowing that degradation, sildenafil allows the nitric oxide-triggered vascular relaxation to produce and sustain an erection when sexual arousal initiates the signaling cascade.
Clinical trial data from the original approval studies found response rates of approximately 60–70% at 50mg and 80% at 100mg in men with organic ED. Real-world response rates are typically lower, partly because many men try sildenafil under suboptimal conditions — after a heavy meal, at 25mg, without adequate arousal — and conclude it does not work before establishing that optimized conditions were met.
Food is the most clinically important variable for sildenafil specifically. High-fat meals delay peak plasma concentration in some pharmacokinetic studies by 60 minutes or more, with total absorption also reduced. This explains why men who switch from sildenafil to tadalafil often find that tadalafil “works better” even at equivalent pharmacological potency — tadalafil’s food interaction is substantially less pronounced. Sublingual delivery addresses this limitation by routing absorption through oral mucosa rather than the gastrointestinal tract, which is the pharmacokinetic rationale for sublingual sildenafil formulations used in some compounded products.
Tadalafil — Research Overview
Tadalafil’s clinical differentiator is duration — its 17.5-hour half-life produces a 36-hour effective window that no other PDE5 inhibitor in this class can match, and it is the only PDE5 inhibitor FDA-approved for daily low-dose use.
Multiple phase III trials confirmed significant improvements in International Index of Erectile Function (IIEF) scores across organic, psychogenic, and mixed-etiology ED for both on-demand and daily dosing protocols. Daily low-dose tadalafil (2.5–5mg) additionally showed secondary benefits in men with comorbid benign prostatic hyperplasia — tadalafil 5mg carries a separate FDA approval for BPH, making it the only PDE5 inhibitor with dual approval for both conditions.
Tadalafil is substantially less affected by food than sildenafil. High-fat meals do not significantly alter absorption or Tmax, making it more predictable for men whose sexual activity typically occurs around meals. This is the primary reason it tends to be the first switch recommendation when food-timing unreliability is identified as a contributing factor to inadequate sildenafil response.
Vardenafil — Research Overview
Vardenafil shares the same PDE5 inhibition mechanism as sildenafil and tadalafil but carries one important safety distinction: a QT interval prolongation caution that neither sildenafil nor tadalafil shares at the same specificity level.
Published pharmacokinetic studies suggest onset as fast as 15 minutes under fasting conditions for some patients, though individual response varies considerably. Its effective window is similar to sildenafil — approximately 4–5 hours. Bioavailability is moderately affected by high-fat meals, similar to sildenafil but generally less pronounced.
The QT prolongation caution is most clinically relevant for men taking Class I or III antiarrhythmic medications (quinidine, procainamide, amiodarone, sotalol) or those with documented QT prolongation conditions. Any cardiac rhythm history must be disclosed to the prescribing physician before vardenafil is considered. Vardenafil is the least commonly prescribed of the three major PDE5 inhibitors partly because of this caution, and partly because tadalafil’s duration advantage makes it the default second-line option when sildenafil underperforms. Its inclusion in compounded multi-ingredient formulations including MEDVi QUAD is specifically positioned around the rapid-onset characteristic.
Apomorphine — How It Differs From PDE5 Inhibitors
Apomorphine belongs to a completely different pharmacological class from the three PDE5 inhibitors — it is a central dopamine agonist working in the brain, not a peripheral vascular agent working in penile tissue.
Its US FDA approval is for acute intermittent treatment of “off” episodes in advanced Parkinson’s disease, administered via subcutaneous injection in that clinical context. It is not FDA-approved in the United States for erectile dysfunction. A systematic review and meta-analysis published in the Archives of Sexual Behavior found sublingual apomorphine generally well-tolerated at 2mg and 3mg doses, with adverse events increasing at higher doses. (Source: PubMed — Archives of Sexual Behavior, 2020.) It was marketed internationally as Uprima for ED in some countries, but US FDA approval for this indication does not exist.
The clinical rationale for including apomorphine alongside PDE5 inhibitors in a compounded ED formulation is that it addresses a different pathway — the neurological arousal initiation step that sits upstream of the vascular mechanism. Men whose ED has a significant desire-related or neurological component alongside the vascular issue may not achieve adequate response from PDE5 inhibition alone, because PDE5 inhibitors only address the downstream vascular half of the erectile response cascade. Whether apomorphine at the doses used in compounded sublingual formulations produces clinically meaningful arousal support for a specific individual is a question for the prescribing clinician, not for a product page.
How These Components Work Together
The clinical rationale for combining all three PDE5 inhibitors with apomorphine is multi-pathway coverage — each ingredient addressing a dimension of erectile function the others cannot fully cover on their own. Vardenafil provides rapid onset, sildenafil provides peak vascular strength, tadalafil provides extended duration, and apomorphine provides the central neurological arousal initiation step that the entire PDE5 class leaves unaddressed.
In practice, combining three PDE5 inhibitors amplifies both the therapeutic potential and the cardiovascular load compared to any single ingredient. This is not inherently unsafe under physician supervision with appropriate dosing — but it is exactly why these formulations require a clinical evaluation before prescribing. The prescribing clinician calibrates dose ratios based on individual patient health, contraindications, and treatment history. Asking the clinician specifically what dose of each component has been prescribed, and why, is the right question at that evaluation.
What This Means for Product Selection
The evidence-based sequence for men starting ED treatment is single-ingredient first — and most men who conclude single-ingredient therapy has failed have not completed an optimized trial.
Generic sildenafil or tadalafil at appropriate doses, under optimized conditions (light meal or empty stomach for sildenafil, adequate onset time allowed, arousal present), for a sufficient trial of 6–8 doses — this is the established clinical protocol. Most men who conclude that single-ingredient therapy does not work have tried it once or twice at a low dose on a full stomach without adequate arousal and drawn a conclusion from an uncontrolled experiment.
For men who have genuinely completed an optimized single-ingredient trial and found the results inadequate, a multi-pathway compounded approach may be worth discussing with a prescribing clinician. The Compounded ED Telehealth Comparison covers the leading programs in this space including MEDVi QUAD, Rugiet, BraveRx, Ro Sparks, and BlueChew GOLD. The MEDVi QUAD review covers that specific program’s verified facts, intake process concerns, and policy terms in detail.
For the full drug interaction and contraindication profile across this medication class — including the absolute nitrate contraindication — read the ED Medication Safety Guide. For the mechanism context behind why the vascular pathway exists and what lifestyle variables modify it, read How Erectile Dysfunction Works.
Frequently Asked Questions
What is the difference between sildenafil and tadalafil? The primary clinical difference is duration. Sildenafil has a half-life of approximately 3–5 hours and an effective window of 4–6 hours. Tadalafil has a half-life of approximately 17.5 hours and an effective window of up to 36 hours, and is available for daily low-dose use. Tadalafil is also substantially less affected by food. Men who find sildenafil unreliable due to meal timing typically respond better to tadalafil — not because tadalafil is stronger, but because the food interaction variable is removed.
How long does sildenafil take to work? Sildenafil reaches peak plasma concentration in 30–60 minutes under fasting conditions. A high-fat meal can delay peak concentration by up to 60 additional minutes. Sublingual formulations reduce this food interaction through oral mucosal absorption, bypassing the gastric processing step.
Why does vardenafil have a QT prolongation warning? Vardenafil carries a specific prescribing caution regarding QT interval effects that sildenafil and tadalafil do not share at the same specificity level. This is most relevant for men on antiarrhythmic medications or with documented QT prolongation conditions. Any cardiac rhythm history must be disclosed to the prescribing physician before vardenafil is considered.
What is apomorphine and how does it differ from PDE5 inhibitors? Apomorphine is a central dopamine agonist working in the brain, not a peripheral vascular agent. Its US FDA approval covers Parkinson’s disease “off” episodes — not erectile dysfunction. Its inclusion in compounded ED formulations is a clinician-directed decision targeting the neurological arousal dimension that PDE5 inhibitors alone cannot address.
What does first-pass metabolism mean for ED medication? First-pass metabolism is the liver’s processing of oral medications before they reach systemic circulation, which reduces effective dose and adds time to onset. Sublingual delivery bypasses this step through oral mucosal absorption — the pharmacokinetic rationale behind faster-onset claims for sublingual ED formulations.
Can you take sildenafil and tadalafil together? Only under direct physician supervision with calibrated dose ratios — as in compounded formulations where a clinician prescribes specific amounts based on complete patient history. Self-administering multiple PDE5 inhibitors without clinical oversight is not appropriate.
This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require physician evaluation before use. Individual results vary. Always consult a qualified healthcare provider before starting any prescription treatment.
Leave a Reply